The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells

We previously showed that tumor-derived heregulin, a ligand for HER3, is associated with both de novo and acquired resistance to cetuximab. We have now examined whether patritumab, a novel neutralizing monoclonal antibody to HER3, is able to overcome such resistance. Human colorectal cancer (DiFi) c...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawakami, Hisato, Okamoto, Isamu, Yonesaka, Kimio, Okamoto, Kunio, Shibata, Kiyoko, Shinkai, Yume, Sakamoto, Haruka, Kitano, Michiko, Tamura, Takao, Nishio, Kazuto, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4323007/
https://www.ncbi.nlm.nih.gov/pubmed/25474137

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4323007/
https://www.ncbi.nlm.nih.gov/pubmed/25474137

Ejemplares similares